| Document |
Document Title |
|
WO/2022/168755A1 |
The present invention provides a nonaqueous electrolyte solution comprising: (I) at least one compound selected from the group consisting of compounds represented by general formula (1) in the description (for example, compounds represen...
|
|
WO/2022/166767A1 |
Disclosed are a pharmaceutically acceptable salt of an HA inhibitor (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridine-4-yl) benzo[d]oxazol-5-yl) cyclopropyl-1-carboxamide, or a h...
|
|
WO/2022/163843A1 |
Provided are a compound having high PIM2 inhibitory activity, and a PIM2 inhibitor and a pharmaceutical composition that contain the compound. This PIM2 inhibitor contains a compound represented by formula (1) (in the formula, A is a ben...
|
|
WO/2022/165198A1 |
A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut...
|
|
WO/2022/158758A1 |
Provided is an organic compound which contributes to substantial improvements in the luminous efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention c...
|
|
WO/2022/156737A1 |
Disclosed are a crystal form of a compound (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridin-4-yl) benzo [d] oxazol-5-yl) cyclopropyl-1-carboxamide having a structure of formula (...
|
|
WO/2022/159445A1 |
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...
|
|
WO/2022/146086A1 |
The present invention relates to: a compound that is sensitive to γ-hydroxybutyric acid (GHB)-based compounds, and thus changes color; and an application thereof, and since the GHB-based compound-sensitive chromogenic compound of the pr...
|
|
WO/2022/136366A1 |
The present invention relates to a novel method for producing NCA compounds. The invention also relates to a novel use of a peptide coupling agent. The method according to the invention enables NCA compounds to be obtained from α-amino ...
|
|
WO/2022/140520A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/132696A1 |
The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psy...
|
|
WO/2022/127704A1 |
Disclosed are a method for preparing a carboxyl cyclic acid anhydride and a prepared product thereof. A method for preparing a compound of formula (II), comprising the steps of reacting a compound of formula (I) with a cyclization reagen...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/121228A1 |
Disclosed are a preparation and an application of an oxazole and thiazole histone deacetylase (HDAC) inhibitor. The chemical structure of the inhibitor is represented by formula (I). The inhibitor has relatively strong inhibitory activit...
|
|
WO/2022/112140A1 |
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/109362A1 |
This disclosure relates to aryl amidines of Formula (I) and their use as fungicides.
|
|
WO/2022/107166A1 |
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.
|
|
WO/2022/106589A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/100099A1 |
An organic compound, a mixture, a composition and an organic electroluminescence device. The organic compound has a high extinction coefficient in the ultraviolet region; has a high refractive index in the visible light region; can be us...
|
|
WO/2022/095569A1 |
Disclosed are a heterocyclic compound for an immune checkpoint inhibitor capable of blocking a VISTA signaling pathway, and a preparation method therefor and a use thereof. The compound is as represented by formula I. The compound has a ...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
|
WO/2022/087719A1 |
Provided are methods of treating SpA, uses for treating SpA and compositions for treating SpA. The methods involve administering a MIF inhibitor to a subject in need thereof. The MIF inhibitor can be a compound or an anti-MIF antibody.
|
|
WO/2022/084790A1 |
The present invention relates to process for preparation of crystalline Form 4 of tafamidis. The present invention also relates to salts of tafamidis and process of preparation of salts of tafamidis. The present invention also relates to...
|
|
WO/2022/083728A1 |
Disclosed are an intermediate of pregabalin and a preparation method therefor. Provided are a compound as represented by formula (I) and a preparation method therefor. The preparation method for the compound as represented by formula (I)...
|
|
WO/2022/080696A1 |
Provided is a high-refractive-index benzazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2022/078294A1 |
The present disclosure provides substituted heteroaryl compounds and use thereof, also provides compounds or pharmaceutically acceptable salts or solvates thereof as PAD inhibitors and their use in treatment of a disease or disorder.
|
|
WO/2022/077196A1 |
Disclosed is an environmentally friendly preparation method for a substituted oxazole compound, said method uses an N-substituted formyl-α-substituted glycinate as a starting material, and a substituted oxazole compound is obtained unde...
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/074068A1 |
The present invention describes disorazoles and their analogues as described in formula III wherein the variables are defined in the description, or pharmaceutically acceptable salts thereof. Described is also a novel synthetic pathway f...
|
|
WO/2022/072820A1 |
The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2- acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoa
te: for subcutaneous administration to a subject, and pharmaceutical compositions, pharmaceutical...
|
|
WO/2022/062288A1 |
Disclosed are an aniline anhydride, a preparation method therefor, and a polyaminoacid graft chain. In the presence of an acid binding agent, an addition-elimination reaction is carried out between N-phenyl amino acid and Boc anhydride t...
|
|
WO/2022/058733A1 |
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...
|
|
WO/2022/053660A2 |
The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X1 being S or O, X2 being S or O and at least one of X1 and X2 being S R2 H or C1-4-alkyl, R3 H or C1-4-alkyl R6 and R7 are hydrogen ...
|
|
WO/2022/053318A1 |
The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic reagents and reduce salts by-products with high efficiency, wherein R1 is H, or lower alkyl or aryl optionally substitut...
|
|
WO/2022/053317A1 |
The present invention provides a process for producing oxazole compounds by direct cyclodehydration of acyloxy enamines in the presence of anhydride. According to the present invention, the oxazole compounds can be produced in a higher y...
|
|
WO/2022/049376A1 |
The invention relates to compounds of formula (I): and related aspects.
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/038224A1 |
A method for the preparation of an alpha-substituted carbonyl compound or an alpha- substituted nitrile compound carrying an aryl or heteroaryl group as an alpha-substituent, said method comprising reacting a sulfoxide compound S1 compri...
|
|
WO/2022/038356A1 |
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...
|
|
WO/2022/040324A1 |
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).
|
|
WO/2022/029357A1 |
The present invention relates to a compound 1 or 2 or a composition comprising same. The present invention also relates to a method for producing a compound 1 or 2, and the use thereof to detect GHB in drinks and urine. The invention als...
|
|
WO/2022/028941A1 |
The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic and corrosive reagent, and salts by-products and has high efficiency,formula (I). Wherein R is H, or lower alkyl or aryl...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/009221A1 |
The present disclosure relates to novel solid forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of Formula (I) and it pharmaceutically acceptable salts thereof.
|
|
WO/2021/261851A1 |
The present invention provides an organic electric element and an electronic device comprising the organic electric element, the organic electric element comprising an anode, a cathode, and an organic layer and a capping layer formed bet...
|
